News

Stay up to date on NKGen Biotech’s company news and announcements.

Press Releases

2022

Yong Ben, M.D. Joins NKGen Biotech as Scientific and Clinical Advisor

August 3, 2022

NKGen Biotech Announces Appointment of Jill M. Jene, PhD as Chief Business Officer

August 1, 2022

NKGen Biotech to Participate in Truist Securities Cell Therapy Symposium

June 21, 2022

NKGen Biotech To Present SNK01 Clinical Data at the 2022 ASCO Annual Meeting

May 26, 2022

NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

May 5, 2022

NKGen Biotech Announces Three SNK01 Abstracts to be Presented at the 2022 ASCO Annual Meeting

May 2, 2022

2021

NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

November 15, 2021

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

November 8, 2021

NKGen Biotech Announces Acceptance of SNK01 Abstract for Presentation at the 2021 Connective Tissue Oncology Society Annual Meeting

October 20, 2021

NKGen Biotech to Participate in the Virtual Solebury Trout Fall Private Company Showcase Co-hosted with BMO

October 7, 2021

NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

October 4, 2021

NKGen Biotech Announces Appointment of Steven Cha, MD as Chief Medical Officer

April 15, 2021

NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC

April 13, 2021

NKGen Biotech Announces Appointment of Philip Moody as Chief Financial Officer

April 7, 2021

NKMax America Announces Corporate Name Change to NKGen Biotech

April 2, 2021

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

March 31, 2021

NKMax America Announces Key Leadership Appointment

February 4, 2021

2020

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

October 20, 2020

NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer

September 8, 2020

NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors.

August 31, 2020

NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers

June 2, 2020

NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference

May 29, 2020

NKMax America To Present Data from Natural Killer Cell Immunotherapy Clinical Program at the ASCO20 Virtual Scientific Program

April 30, 2020

NKMax America Announces Acceptance of Three Abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting

March 31, 2020

NKMax America to Present at the Upcoming NIH-AACR Cancer, Autoimmunity, and Immunology Conference

March 17, 2020

NKMax America to Present at Immuno-Oncology Summit Europe 2020

March 9, 2020

NKMax America to Present Corporate Overview at the Cowen & Company 40th Annual Health Care Conference

March 3, 2020

2019

NKMax America Announces Executive Advisory Board

November 11, 2019

NKMax America Announces New cGMP Manufacturing Facility for Production of SNK Cell Therapy

September 9, 2019

NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer

August 13, 2019

NKMax America to Present at 2019 Innate Immunity Conference

March 19, 2019

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer

March 5, 2019

NKGen Biotech Events

Check back soon for upcoming events!

NKGen on Social Media

Follow NKGen on social media to keep up-to-date on the latest company news and the science of Natural Killer cells!

Science

NK Cell Function & Disease

Scientific Publications

NKGen Biotech, Inc.

Corporate Office
19700 Fairchild Rd, Suite #300
Irvine, CA 92612

GMP Facility
3001 Daimler Street
Santa Ana, CA 92705

Tel: 949.396.6830
info@nkgenbiotech.com

News

Press Releases

Subscribe to NKGen News Updates

NKGen Biotech Events

NKGen on Social Media